Public Employees Retirement Association of Colorado Sells 741 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Public Employees Retirement Association of Colorado reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% in the 3rd quarter, Holdings Channel reports. The firm owned 460,531 shares of the medical research company’s stock after selling 741 shares during the quarter. Thermo Fisher Scientific comprises approximately 0.8% of Public Employees Retirement Association of Colorado’s investment portfolio, making the stock its 27th biggest position. Public Employees Retirement Association of Colorado’s holdings in Thermo Fisher Scientific were worth $134,139,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of TMO. Vanguard Group Inc. boosted its holdings in Thermo Fisher Scientific by 1.2% during the second quarter. Vanguard Group Inc. now owns 30,670,985 shares of the medical research company’s stock worth $9,007,455,000 after buying an additional 378,260 shares during the last quarter. BlackRock Inc. boosted its stake in Thermo Fisher Scientific by 1.4% in the 2nd quarter. BlackRock Inc. now owns 27,643,905 shares of the medical research company’s stock valued at $8,118,461,000 after purchasing an additional 392,227 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Thermo Fisher Scientific by 2.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,139,325 shares of the medical research company’s stock valued at $5,033,477,000 after purchasing an additional 395,830 shares during the period. Bank of New York Mellon Corp boosted its stake in Thermo Fisher Scientific by 3.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,559,667 shares of the medical research company’s stock valued at $1,045,404,000 after purchasing an additional 102,504 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in Thermo Fisher Scientific by 22.9% in the 2nd quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock valued at $877,186,000 after purchasing an additional 555,802 shares during the period. 88.24% of the stock is owned by hedge funds and other institutional investors.

TMO has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Credit Suisse Group restated a “buy” rating and issued a $310.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Robert W. Baird boosted their price target on Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. ValuEngine downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Barclays set a $330.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Monday, July 15th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $314.45.

Shares of NYSE:TMO traded up $1.11 during trading on Friday, reaching $294.65. 773,005 shares of the company traded hands, compared to its average volume of 1,323,858. The company’s 50 day moving average is $290.14 and its two-hundred day moving average is $283.57. The firm has a market capitalization of $117.34 billion, a PE ratio of 26.50, a PEG ratio of 1.90 and a beta of 1.14. The company has a quick ratio of 1.23, a current ratio of 1.80 and a debt-to-equity ratio of 0.56. Thermo Fisher Scientific Inc. has a 52 week low of $208.34 and a 52 week high of $306.00.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, beating analysts’ consensus estimates of $2.88 by $0.06. The firm had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.19 billion. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.62 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Tuesday, December 17th will be given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 6.83%.

In other news, CEO Marc N. Casper sold 2,271 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $298.00, for a total transaction of $676,758.00. Following the completion of the sale, the chief executive officer now directly owns 283,502 shares in the company, valued at approximately $84,483,596. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 47,729 shares of the company’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $295.88, for a total value of $14,122,056.52. Following the sale, the chief executive officer now owns 328,960 shares of the company’s stock, valued at $97,332,684.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,833 shares of company stock valued at $15,299,095. Corporate insiders own 0.45% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.